Assetmark Inc. Has $39,000 Position in AtriCure, Inc. (NASDAQ:ATRC)

Assetmark Inc. cut its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 95.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,406 shares of the medical device company's stock after selling 27,910 shares during the period. Assetmark Inc.'s holdings in AtriCure were worth $39,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Arcadia Investment Management Corp MI purchased a new stake in shares of AtriCure during the 3rd quarter worth about $28,000. Comerica Bank grew its position in AtriCure by 70.5% in the first quarter. Comerica Bank now owns 2,522 shares of the medical device company's stock worth $77,000 after acquiring an additional 1,043 shares in the last quarter. nVerses Capital LLC increased its stake in shares of AtriCure by 733.3% during the 3rd quarter. nVerses Capital LLC now owns 5,000 shares of the medical device company's stock worth $140,000 after purchasing an additional 4,400 shares during the last quarter. Quest Partners LLC raised its holdings in shares of AtriCure by 38.3% during the 2nd quarter. Quest Partners LLC now owns 5,868 shares of the medical device company's stock valued at $134,000 after purchasing an additional 1,626 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC acquired a new stake in shares of AtriCure in the 1st quarter valued at $224,000. 99.11% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ATRC has been the subject of several analyst reports. Oppenheimer boosted their target price on AtriCure from $32.00 to $36.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. Needham & Company LLC raised their target price on shares of AtriCure from $34.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Canaccord Genuity Group boosted their target price on shares of AtriCure from $49.00 to $53.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. raised their price target on AtriCure from $30.00 to $40.00 and gave the company an "overweight" rating in a research report on Wednesday, October 30th. Finally, UBS Group increased their target price on AtriCure from $35.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, AtriCure has an average rating of "Moderate Buy" and a consensus target price of $43.11.

AtriCure Stock Performance

ATRC stock traded up $1.23 during midday trading on Tuesday, hitting $35.95. The stock had a trading volume of 112,284 shares, compared to its average volume of 722,452. The stock has a 50-day simple moving average of $30.24 and a 200 day simple moving average of $25.52. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -42.39 and a beta of 1.41. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $43.00. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. The company had revenue of $115.91 million for the quarter, compared to the consensus estimate of $112.23 million. During the same period in the previous year, the business earned ($0.20) earnings per share. The company's quarterly revenue was up 17.9% on a year-over-year basis. As a group, equities research analysts anticipate that AtriCure, Inc. will post -0.72 earnings per share for the current year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.